NYSE:RCUS

Arcus Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy RCUS

*Your capital is at risk

$28.19

-0.0600 (-0.212%)

At Close: Jul 31, 2026

Arcus Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -68.07. In total, the insiders bought 1.79M and sold 739.53K RCUS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-68.07
● Buy	1.79M shares
● Sell	739.53K shares
48% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Jul 10, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -68.07. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 29, 2025 Sell	Common Stock S-Sale	Jaen Juan C. President	CEO / President	800 Value: $17.6K
Oct 28, 2025 Sell	Common Stock S-Sale	Jaen Juan C. President	CEO / President	19 019 Value: $383.9K
Oct 28, 2025 Sell	Common Stock S-Sale	Goeltz Ii Robert C. Chief Financial Officer	C-Suite Officer	5 000 Value: $100.0K
Oct 08, 2025 Buy	Common Stock M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	37 792 Value: $46.4K
Oct 08, 2025 Sell	Common Stock S-Sale	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	37 792 Value: $568.6K
Oct 08, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	37 792 Value: $46.4K
Oct 08, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	37 792 Value: $46.4K
Oct 08, 2025 Sell	Common Stock S-Sale	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	37 792 Value: $568.6K
Oct 08, 2025 Buy	Common Stock M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	37 792 Value: $46.4K
Oct 06, 2025 Buy	Common Stock M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	12 500 Value: $15.3K
Oct 06, 2025 Sell	Common Stock S-Sale	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	12 500 Value: $181.8K
Oct 06, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	12 500 Value: $15.3K
Oct 06, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	12 500 Value: $15.3K
Oct 06, 2025 Sell	Common Stock S-Sale	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	12 500 Value: $181.8K
Oct 06, 2025 Buy	Common Stock M-Exempt	Jarrett Jennifer Chief Operating Officer	C-Suite Officer	12 500 Value: $15.3K
Sep 29, 2025 Sell	Common Stock S-Sale	Azoy Alexander Chief Accounting Officer	Officer	2 831 Value: $36.8K
Sep 29, 2025 Sell	Common Stock S-Sale	Azoy Alexander Chief Accounting Officer	Officer	2 831 Value: $36.8K
Sep 05, 2025 Sell	Common Stock S-Sale	Azoy Alexander Chief Accounting Officer	Officer	1 579 Value: $18.8K
Sep 05, 2025 Sell	Common Stock S-Sale	Azoy Alexander Chief Accounting Officer	Officer	1 579 Value: $18.8K
Jun 10, 2025 Buy	Common Stock A-Award	Perlman Andrew J Director	Director	13 300 Value: $133.3K
Jun 10, 2025 Buy	Stock Option (Right to Buy) A-Award	Perlman Andrew J Director	Director	38 300 Value: $383.8K
Jun 10, 2025 Buy	Common Stock A-Award	Lambert Nicole Director	Director	13 300 Value: $133.3K
Jun 10, 2025 Buy	Stock Option (Right to Buy) A-Award	Lambert Nicole Director	Director	38 300 Value: $383.8K
Jun 10, 2025 Buy	Common Stock A-Award	Kaneko Yasunori Director	Director	13 300 Value: $133.3K
Jun 10, 2025 Buy	Stock Option (Right to Buy) A-Award	Kaneko Yasunori Director	Director	38 300 Value: $383.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCUS BIOSCIENCES INC.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...

Read Full Profile Here